

Synthesis of 6(*S*)-Amino-7-cyclohexyl-4,4-difluoro-3(*R*),5(*R*)-dihydroxy-2-methylheptane, a Novel Dipeptide Mimic

Hing L. Sham,* Cheryl A. Rempel, Herman Stein, and Jerome Cohen


Abbott Laboratories, Pharmaceutical Discovery Division, Abbott Park, Illinois 60064-3500, USA

The incorporation of the novel dipeptide mimic (**1**), synthesized *via* Boc-L-cyclohexylalaninol (Boc = *t*-butoxycarbonyl), into a dipeptide sequence has led to a very potent renin inhibitor.

The inhibition of the enzyme renin, which cleaves its natural substrate angiotensinogen (a large protein) at the Leu(10)-Val(11) amide bond, is an important area for study of blood pressure regulation.¹ Over the past decade, several transition

state mimics of the Leu-Val scissile bond have been reported and these include statine,^{2a} hydroxyethylene isosteres,^{2b} amino glycols,^{2c} and fluoroketones.^{2d} We report here the synthesis of a novel transition state mimic of Leu(10)-Val(11): 6(*S*)-amino-7-cyclohexyl-4,4-difluoro-3(*R*),5(*R*)-dihydroxy-2-methylheptane (**1**).

Oxidation of Boc-L-cyclohexylalaninol (**3**) (Boc = *t*-butoxycarbonyl) by the Swern method³ provided the corresponding aldehyde which, when reacted with ethyl bromodifluoroacetate and activated zinc under sonicating conditions,⁴ gave the difluorostatine (**4a**) and its β -isomer (**4b**) in a ratio of 2:1 in 70% yield. The absolute stereochemistry of the hydroxy group of these two diastereoisomers was established as follows: separate deprotection of (**4a**) and (**4b**) and cyclization with phosgene gave the corresponding oxazolidinones (**5a**) and (**5b**). The 300 MHz ¹H NMR spectrum (CDCl₃) of (**5a**) [δ 4.60 ($J_{3,4}$ 4.5 Hz, H-3)] and (**5b**) [δ 5.05 ($J_{3,4}$ 8.5 Hz, H-3)] compared well with the reported data^{2a} for the oxazolidinones of (3*S*,4*S*)-statine [δ 4.50 ($J_{3,4}$ 5.0 Hz, H-3)] and (3*R*,4*S*)-statine [δ 5.10 ($J_{3,4}$ 8.8 Hz, H-3)]. Hydrolysis of the ethyl ester in (**5a**), followed by reaction of the resulting carboxylic acid



Scheme 1. Reagents: i, (COCl)₂-dimethyl sulphoxide; ii, Zn, ethyl bromodifluoroacetate; iii, HCl then COCl₂ in toluene; iv, lithium hydroxide; v, isopropyl-lithium; vi, sodium borohydride; vii, Ba(OH)₂ then Cbz-NOS; viii, 2-methoxypropene/*p*-TsOH.

with isopropyl-lithium⁵ in tetrahydrofuran provided the ketone (**6**) in 72% yield (two steps). Reduction of the ketone with sodium borohydride in methanol at 0 °C, followed by hydrolysis of the oxazolidinone ring and protection of the amino function with *N*-(benzyloxycarbonyloxy)succinimide (Cbz-NOS) provided the alcohols (**7a**) and (**7b**) in the ratio of 9:1 in 70% overall yield. The relative stereochemistry of the two hydroxy groups in (**7a**) and (**7b**) was established by synthesizing the corresponding acetonides (**8a**) and (**8b**) by reaction with 2-methoxypropene catalysed by *p*-MeC₆H₄-SO₃H (*p*-TsOH). The 2D-NOE NMR experiment was done on (**8a**) and (**8b**). No NOE effect was observed between the axial and equatorial hydrogens in (**8a**) and a definite NOE effect was observed between the two axial hydrogens in (**8b**). Removal of the benzyloxycarbonyl (Cbz) protecting group in (**7a**) gave the novel dipeptide mimic (**1**) which was coupled to Boc-Phe-Leu-OH using dicyclohexylcarbodiimide in *N,N*-dimethylformamide to give compound (**2**).[†] Compound (**2**) is a very potent inhibitor of human renin (IC₅₀ 6.5 × 10⁻¹⁰ M).

[†] All new compounds gave satisfactory spectral data and elemental analysis.

In conclusion, a stereoselective synthesis of (**1**), which is an excellent dipeptide mimic of the Leu(10)-Val(11) cleavage site of angiotensinogen is described. Incorporation of (**1**) in a short peptide sequence resulted in a very potent inhibitor of human renin.

Received, 12th March 1990; Com. 0/01090A

References

- 1 I. A. Reid, *Arch. Intern. Med.*, 1986, **145**, 1475.
- 2 (a) D. H. Rich and E. T. Sun, *J. Med. Chem.*, 1980, **28**, 27; (b) M. Szelke, D. M. Jones, B. Atrash, A. Hallet, and B. Leckie, in 'Peptides, Structure and Function,' eds. D. H. Rich and V. J. Hruby, 1983, p. 579; (c) J. R. Luly, N. Maung, A. Fung, and J. J. Plattner, *J. Med. Chem.*, 1988, **31**, 2264; (d) H. L. Sham, H. Stein, C. Rempel, J. Cohen, and J. J. Plattner, *FEBS Lett.*, 1987, **220**, 299.
- 3 K. Omura and D. Swern, *Tetrahedron*, 1978, **34**, 1651.
- 4 S. Thaisivongs, D. Pals, W. M. Kati, S. R. Turner, L. Thomasco, and W. Watt, *J. Med. Chem.*, 1986, **29**, 2080.
- 5 C. G. Knudsen and H. Rapoport, *J. Org. Chem.*, 1983, **48**, 2260.